Ensho Therapeutics revealed that it has secured a portfolio of oral α4β7 integrin inhibitors under an exclusive global license agreement with EA Pharma Co., Ltd., a division of Eisai Co., Ltd.
The U.S. Food and Drug Administration (FDA) approved fenfluramine on June 25, 2020, for the treatment of seizures associated with Dravet syndrome in patients two years of age and older.
Bicara Therapeutics Announces New Interim Phase 1/1b Data for Ficerafusp Alfa (BCA101) in First-Line HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
Jul 2nd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.